The incidence of severe reactions is highest during the first 2 months of therapy, and is associated with advanced age, renal dysfunction, and presence of the HLA-B*5,801 variant (Roujeau et al., 1995; Strilchuk et al., 2019; Stamp and Chapman, 2020). The gene discussed is HLA-B; the disease is Abnormal renal physiology.